Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1191405.RAil9pj6UeklIaOiSFAivA5u3YeR2uaD-kuCQ-Xe9JIoU130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1191405.RAil9pj6UeklIaOiSFAivA5u3YeR2uaD-kuCQ-Xe9JIoU130_assertion type Assertion NP1191405.RAil9pj6UeklIaOiSFAivA5u3YeR2uaD-kuCQ-Xe9JIoU130_head.
- NP1191405.RAil9pj6UeklIaOiSFAivA5u3YeR2uaD-kuCQ-Xe9JIoU130_assertion description "[Relapse-free (RFS) and overall survival (OS) of AML+13 patients were inferior compared to other ELN Intermediate-II patients (n=855) (median RFS, 7.8 vs 14.1 months, P = .006; median OS 9.3 vs. 14.8 months, P = .004).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1191405.RAil9pj6UeklIaOiSFAivA5u3YeR2uaD-kuCQ-Xe9JIoU130_provenance.
- NP1191405.RAil9pj6UeklIaOiSFAivA5u3YeR2uaD-kuCQ-Xe9JIoU130_assertion evidence source_evidence_literature NP1191405.RAil9pj6UeklIaOiSFAivA5u3YeR2uaD-kuCQ-Xe9JIoU130_provenance.
- NP1191405.RAil9pj6UeklIaOiSFAivA5u3YeR2uaD-kuCQ-Xe9JIoU130_assertion SIO_000772 24923295 NP1191405.RAil9pj6UeklIaOiSFAivA5u3YeR2uaD-kuCQ-Xe9JIoU130_provenance.
- NP1191405.RAil9pj6UeklIaOiSFAivA5u3YeR2uaD-kuCQ-Xe9JIoU130_assertion wasDerivedFrom befree-2016 NP1191405.RAil9pj6UeklIaOiSFAivA5u3YeR2uaD-kuCQ-Xe9JIoU130_provenance.
- NP1191405.RAil9pj6UeklIaOiSFAivA5u3YeR2uaD-kuCQ-Xe9JIoU130_assertion wasGeneratedBy ECO_0000203 NP1191405.RAil9pj6UeklIaOiSFAivA5u3YeR2uaD-kuCQ-Xe9JIoU130_provenance.